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Background: An increasing number of authors employing intravascular ultrasound (IVUS) and virtual histology
(VH-IVUS) have investigated the effect of statin use on plaque volume (PV) and plaque composition. However,
inconsistent results have been reported. Therefore, we conducted a meta-analysis to determine the appropriate
regimen of statins to effectively stabilize vulnerable coronary plaques.
Methods: Online electronic databases were carefully searched for all relevant studies. We compared mean
values of PV and plaque composition between baseline and follow-up in patients receiving statin therapy. We
pooled treatment effects and calculated mean differences (MD) with the 95% confidence interval (CI) using a
random-effects model. By stratified analyses, we explored the influence of clinical presentation, dose and
duration of statin treatment, and low-density lipoprotein-cholesterol (LDL-C) levels on the effects of statins.
Results: Seventeen studies involving 2,171 patients were analyzed. Statin therapy significantly decreased PV
(−5.3 mm3; 95% CI: –3.3 mm3 to −7.2 mm3; P < 0.001), without heterogeneity. When considering the dose and
duration of statins used, only subgroups employing a high dose and long duration demonstrated a significant
reduction in PV (p < 0.001). A significant decrease in PV was noted if achieved LDL-C levels were <100 mg/dL
(p < 0.001). Statin treatment could induce a twofold decrease in PV in patients with acute coronary syndrome
(ACS) compared with that observed in patients with stable angina pectoris (SAP). A regressive trend was seen
for necrotic core volume (MD: –2.1 mm3; 95% CI: –4.7 mm3 to 0.5 mm3, P = 0.11). However, statin use did not
induce a significant change for fibrotic, fibro-fatty, or dense calcium compositions.
Conclusions: Our meta-analysis demonstrated that statin therapy (especially that involving a high dose and
long duration and achieving <100 mg/dL LDL-C levels) can significantly decrease PV in patients with SAP or
ACS. These data suggested that statins can be used to reduce the atheroma burden for secondary prevention
by appropriately selecting the statin regimen. No significant change in plaque composition was seen after statin
therapy.
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Statin treatment is regarded as one of the most effective
methods for the stabilization of vulnerable atheroscler-
otic plaques, and is associated with improvements in
outcome in patients with coronary heart disease (CHD)
[1,2]. Statins have a wide range of biologic effects, in-
cluding a decrease in the level of low-density lipopro-
tein-cholesterol (LDL-C) and high-sensitivity C-reactive* Correspondence: yubodr2009@163.com
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reproduction in any medium, provided the orprotein, as well as a modest increase in the level of high-
density lipoprotein-cholesterol [3]. With respect to sec-
ondary prevention, statins are considered to be essential
in subjects with CHD [4].
Outcomes have been shown to be improved after sta-
tin treatment, but the mechanism by which statins con-
fer cardiovascular benefit is not precisely understood.
Some angiographic studies have shown only minimal
increases in lumen area in target lesions in patients
administered statins [5]. Regression of coronary plaque
volume (PV) and plaque composition as well as a reduc-
tion in plaque vulnerability are presumed to have im-
portant roles. One study employing a meta-analysis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tin treatment [6], whereas no significant decrease in
plaque size was shown by subgroup analyses according
to follow-up time of statin use and LDL-C levels, sug-
gesting that these results were not robust. An increasing
number of intravascular ultrasound (IVUS) and virtual
histology-intravascular ultrasound (VH-IVUS) studies
have demonstrated that statin therapy can result in sig-
nificant changes in PV and plaque composition [7,8].
However, not all studies have suggested that statin ther-
apy can induce a significant reduction in the size and
composition of plaques. These differences among studies
may be due to different statin-administered strategies.
Therefore, determining which regimen of statin adminis-
tration is effective for stabilizing vulnerable coronary
plaques is very important.
In the present study, we aimed to summarize the evi-
dence on the effectiveness of statins on atherosclerosis
development. We also sought to determine the extent to
which such statin-induced changes in plaque compos-
ition was supported by evidence. We therefore under-
took a meta-analysis to investigate if statin therapy can
significantly change PV and plaque composition. By
stratified analyses, we further explored the influence of
clinical presentation, dose and duration of statin treat-




The online electronic databases PubMed, EMBASE, and
Cochrane Clinical Trials were searched carefully using
the following terms: “Intravascular ultrasound” or “IVUS”
and “HMG-CoA reductase inhibitor (s)”, or “statin(s)”, or
“atorvastatin” or “pravastatin” or “simvastatin” or “ceri-
vastatin” or “fluvastatin” or “lovastatin” or “mevastatin”
or “pitavastatin” or “rosuvastatin”. The date range was
1990–2010 and there were no language restrictions. The
literature search was accomplished independently by two
well-trained reviewers. Discussions between the two
reviewers were initiated if there were discrepancies in
search results. Abstracts of conferences and recently
published editorials were checked, as were the reference
lists of identified articles and review articles.
Inclusion criteria
The inclusion criteria for the meta-analysis were: (1)
IVUS and/or VH-IVUS volume analyses at baseline and
follow-up; (2) ≥1 statin therapy group.
Exclusion criteria
Reviews, commentaries, editorials and case reports were
not used. Studies analyzing other drugs, stents, graft dis-
ease, in-stent neointima and animal models were alsoexcluded. We also excluded studies in which: there was
no follow-up; not all patients were evaluated by IVUS or
VH-IVUS; the volumetric parameters of plaques were
not reported.Selection of studies
Two reviewers independently reviewed the articles. Study
selection is summarized in Figure 1. Of 248 relevant
studies, 213 were excluded (Figure 1). Of the remaining
35 potentially appropriate studies, 18 were excluded. Of
these, 8 studies detected area measurements or did not
provide absolute volume measurements; 4 carried out
post-hoc analyses using experimental data from other
studies which were included in our analyses; 2 measured
the remodeling index ; 1 chose the coronary flow reserve
index as the endpoint; 1 investigated patients with dia-
betes mellitus; 1 undertook IVUS at one time point; 1
considered cerivsatatin [9] (which was withdrawn from
the market in 2001 due to its association with fatal
rhabdomyolysis) only in the Discussion section. Conse-
quently, 17 studies including 22 groups with 2,171 sub-
jects were analyzed [10-26].
The main analysis of our study focuses on pre October
2010 papers but that since then 5 studies with 7 groups
[27-31] were published whose principal findings were
shown in the in Additional file 1: Table S1 and Add-
itional file 2: Table S2 but were not included in the for-
mal analysis.Data extraction
Two reviewers independently extracted the following
variables: (i) first author's surname and year of publica-
tion of article; (ii) characteristics of the study population
(sample size, age, sex, presentation); (iii) type and dose
of statin; (iv) duration of follow-up; (v) LDL-C levels at
baseline and follow-up; (vi) VH-IVUS volume data. In-
consistencies in the interpretation of data were discussed
until a consensus was reached. If a study lacked
complete data, the investigators of the primary study
were contacted to provide information.
The methodological quality of the studies included in
the meta-analysis was independently scored by two
reviewers using a validated five-point scale created by
Jadad et al. The scale consists of three items describing
randomization (0–2 points), masking (0–2 points), and
dropouts and withdrawals (0–1 points) in the report of a
randomized controlled trial [20]. A score of 1 is given
for each of the points described. An additional point is
obtained if the method of randomization and/or blinding
is given and is appropriate, whereas one point is
deducted if it is inappropriate. Higher scores indicate
better reporting.
Figure 1 Study selection.
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Before IVUS analyses, based on reproducible landmarks
(e.g., a calcium deposit, stent edge or side branch), the
same segment was identified in the IVUS run at baseline
and at follow-up. IVUS analyses were undertaken once
at baseline and at follow-up by the same independent
experienced investigator who was blinded to the patient
groups. Manual detection of the lumen contour and the
media–adventitia interface was undertaken by an experi-
enced analyst blinded to baseline clinical characteristics
and baseline angiographic characteristics of the lesions.
The external elastic membrane volume and lumen vol-
ume were calculated. The difference between these two
values was defined as PV.
VH-IVUS uses IVUS radiofrequency data to classify an
atherosclerotic plaque into four compositions: fibrous,
fibro-fatty, dense calcium, and necrotic core. These
compositions are assigned color codes of green, greenish
yellow, white and red, respectively. Color-coded tissuemaps are then constructed. Compositions within the
plaque can be identified, as previously validated by pre-
liminary in-vitro and in-vivo studies [32,33]. Fibrous tis-
sue was marked in green, fibro-fatty in yellow, dense
calcium in white and necrotic core in red colors on the
VH-IVUS image. The absolute value of each plaque
composition was also calculated automatically by the
software.
We compared the mean values of PV and plaque com-
position between baseline and follow-up in patients re-
ceiving statin therapy. We further analyzed the effects of
statin treatment on plaque size by clinical presentation,
dose and duration of statin treatment, and LDL-C levels
at follow up.
Statistical analyses
We pooled treatment effects and calculated mean dif-
ferences (MD) with a 95% confidence interval (CI) for
all endpoints by using a random-effects model [34].
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considered the results for heterogeneity to be significant
at P < 0.10 (two-sided). Inconsistency of treatment
effects was calculated for assessing the percentage of
total variance across studies that was due to heterogen-
eity rather than chance. Publication bias was estimated
using funnel plots. A strongly asymmetric plot suggested
the underlying presence of publication bias (i.e., whereby
small studies reporting positive outcomes are more likely
to be published than equally small studies reporting
negative results). RevMan 5.0.23 was used for analyses of
statistical data. P < 0.05 was considered significant. For
assessing the potential impact of publication bias, we calcu-
lated the fail-safe number using the method of Rosenberg
and Orwin's [35]. (The fail-safe number represents the
number of studies needed to make P > 0.05.)
By stratified analyses, we explored the influence of
clinical presentation, dose and duration of statin treat-
ment, and LDL-C levels at follow-up on the effects of
statins. Of the 22 groups, 5 groups investigated patients
with acute coronary syndrome (ACS) and 13 groups
investigated patients with stable angina pectoris (SAP).
When considering the dose and duration of statin ther-
apy, enrolled studies were divided into four subgroups:
subgroup 1, ≤10 mg/day of atorvastatin or an equivalent
dose of other statins and ≤6 months of follow-up; sub-
group 2, ≤10 mg/day of atorvastatin or an equivalent
dose of other statins and >6 months of follow-up; sub-
group 3, >10 mg/day of atorvastatin or an equivalent
dose of other statins and ≤6 months of follow-up; and
subgroup 4, >10 mg/day of atorvastatin or an equivalent
dose of other statins and >6 months of follow-up. When
considering LDL-C levels at follow-up, all enrolled stud-
ies were divided into three subgroups: subgroup 1,
≤70 mg/dL of LDL-C; subgroup 2, 70–100 mg/dL of
LDL-C; and subgroup 3, ≥100 mg/dL of LDL-C.Results
Of the 22 groups, atorvastatin was used in 8 groups,
rosuvastatin in 3 groups, simvastatin in 3 groups, pra-
vastatin in 3 groups, pitavastatin in 1 group, fluvastatin
in 1 group, and different statins in 3 groups (Additional
file 3: Table S3). Each group enrolled mostly men. Of
the 22 groups, 5 groups investigated patients with ACS,
and 13 groups investigated patients with SAP. The
remaining 4 groups did not exclude patients with ACS.
The sample size of the studies was 17–446 patients. The
mean age of patients in the studies was 61 ± 3.5 years
(range, 55–67 years). The mean LDL-C level at baseline
was 128.6 ± 22.6 mg/dL (range, 71–158.3 mg/dL). The
mean LDL-C level at follow-up ranged was 85.3 ±
13.8 mg/dL (range, 60.8–110.4 mg/dL). The duration of
follow up was 1.5–24 months.The PV significantly decreased after statin therapy
(MD: –5.3 mm3; 95% CI: –3.3 to −7.2 mm3; P < 0.001),
without heterogeneity (P = 0.83 and I2 = 0%; Figure 2).
The funnel plot (Figure 3) did not show asymmetry con-
sistent with publication bias. The fail-safe N was 142,
suggesting that 142 additional ‘negative’ studies would
be needed to negate our result. The decrease in PV in
ACS patients was twofold than that observed in SAP
patients (Table 1).
A regressive trend was seen for necrotic core vol-
ume (MD: –2.1 mm3; 95% CI: –4.7 mm3 to 0.5 mm3,
Figure 4), but did not reach statistical significance (P =
0.11). No significant change was noted for the fibrotic,
fibro-fatty, or dense calcium volume (P = 0.87, 0.59, and
0.99, respectively). Non-significant heterogeneity was
detected for the fibrotic, necrotic core or dense calcium
volume, but not for fibro-fatty volume (I2 = 91%).
When considering the dose and duration of statin
therapy, a significant decrease in PV was seen only in
the studies involving administration of >10 mg/day of
atorvastatin or an equivalent dose of other statins and
>6 months of continuous therapy (MD, –5.2 mm3; 95%
CI: –3.1 mm3 to −7.3 mm3; P < 0.001; fail-safe N = 45; 9
groups, 1,520 patients; Table 2), without heterogeneity.
When considering LDL-C levels at follow-up, signifi-
cant decreases in PV were shown in studies with 70–
100 mg/dL of achieved LDL-C levels (MD: –5.7 mm3;
95% CI: –2.7 mm3 to −8.6 mm3; P < 0.001; fail-safe N =
58; 13 groups, 1,372 patients; Table 3), and in the studies
with <70 mg/dL of achieved LDL-C levels (MD:
–5.9 mm3; 95% CI: –2.2 mm3 to −9.6 mm3; P < 0.001;
fail-safe N = 5; 4 groups, 429 patients; Table 3). However,
there was no a significant decrease in PV in studies with
>100 mg/dL of achieved LDL-C levels (P = 0.15). There
was no evidence of heterogeneity for the three
subgroups.
Discussion
The present study demonstrated that statin therapy can
significantly decrease the size of atherosclerotic plaques,
whereas there were no significant changes in plaque
composition. These findings are similar to the findings
in some in-vivo human studies [36]. Our findings are
supported by animal studies, which have demonstrated a
reduction in plaque size and macrophage content as well
as an increase in the amount of interstitial collagen in
atherosclerotic lesions after lipid-lowering therapy (LLT)
[37-39]. One study demonstrated that PV increased by
11.8% in the usual care group [25]. When considering
the dose and duration of statin therapy, a significant de-
crease in PV was noted only in subgroups having a high
dose and long duration of statin therapy. Based on
achieved LDL-C levels, the present study demonstrated
that a significant decrease in plaque size will occur only
Figure 2 Effect of statins on plaque volume. Squares to the left of the vertical line indicate regression of coronary plaques, whereas squares to
the right of the vertical line indicate progression of coronary plaques. The horizontal line through each square represents the 95% confidence
interval (CI). The diamond represents the pooled effect (width of the diamond indicates the 95% CI). Abbreviations: ACS, acute coronary
syndrome; SAP, stable angina pectoris.
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of intensive LDC-L-lowering therapy in high-risk older
subjects with established cardiovascular disease. These
data indicate that coronary artery disease can be
retarded (and even regress) if the favorable levels of
LDL-C that were attained with statin therapy in the
present study are achieved. Statin treatment induced a
twofold decrease in PV in patients with ACS compared
with that seen in patients with SAP, and this difference
may originate from various plaque characteristics be-
tween the two cohorts [40]. Evidence suggests that
patients with ACS have many greater-risk non-culprit
plaques [41]. Multi-slice CT study has demonstrated that
certain characteristics of vulnerable plaques (e.g., posi-
tive vascular remodeling and low plaque density) are
more frequent in ACS lesions than in SAP lesions [42].Some papers published since October 2010 further sup-
ported our conclusion that statin therapy can signifi-
cantly retard or even decrease plaque progression in
patients with coronary artery disease, especially when
patients taking a high dose and long duration of statin
regimen [27,29,31].
Plaque composition is now seen as being much more
important than plaque size and the severity of stenoses.
Plaques containing a soft lipid-rich core are particularly
dangerous because such plaques are unstable and vul-
nerable to rupture, whereby highly thrombogenic pla-
ques are exposed to blood flow [43,44]. Plaques that are
prone to rupture have a large lipid core, occupy >40% of
the total PV, and have a thin fibrous cap (diameter,
<65 μm) [45]. Reduction in the size of the necrotic core
might be one of several requirements for plaque
Figure 3 Graphical representation of publication bias. The dots, each representing one study, conform to a triangular shape: the publication
bias is low.
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tended to decrease in size, but this did not reach statis-
tical significance. Some studies using optical coherence
tomography (OCT) showed that the incidence of plaque
rupture was significantly decreased and that the thick-
ness of the fibrous cap tended to increase with statin
therapy [46]. Based upon VH-IVUS findings, “fibro-
fatty” is defined as fibrous tissue with significant lipid
interspersed in collagen [32]. The interspersed lipids in
fibro-fatty tissue might regress from the atherosclerotic
intima with a reducing continued influx of lipid. Hence,
an accumulation of interstitial collagen in fibrous tissue
might be significantly increased by LLT. However, we
failed to observe significant changes in fibro-fatty vol-
ume in the present study. In agreement with our conclu-
sion, one recent study has demonstrated that statins
does not lead to significant changes in plaque compos-
ition [28]. One explanation for those findings in the
present study could be that the dose of statins selected
in the three groups should be almost equivalent to 10–
20 mg/day of atorvastatin, which is relatively low to be
effective for stabilizing coronary plaques in CHD [13,14].
Further studies are needed to determine the effect of in-
tensive statin therapy on plaque composition. Another
reason for those findings in the present study could be
low statistical power. For primary efficacy, i.e., change inTable 1 Mean differences and 95% CIs in plaque volume achi
Subgroup Number of studies Number of patients
All patients 19 2,171
ACS patients 5 350
SAP patients 13 1,380
Abbreviations: ACS, acute coronary syndrome; PV, plaque volume; SAP, stable anginnecrotic core volume, a sample size of 238 patients
was specified for 80% power and a two-sided α level of
0.025 to detect an expected change of −2 mm3 (assum-
ing a standard deviation (SD) of 10 mm3). Indeed, a sub-
stantial residual risk of clinical events remains in most
patients who have undergone secondary prevention des-
pite the use of statins [47]. In the Scandinavian Simvas-
tatin Survival Study (4S), therapy reduced the relative
risk of coronary events by 30% over 5 years from an
absolute risk of 28% to 19% [48,49]. Novel anti-
atherosclerotic agents in addition to statins may be
needed to more effectively stabilize plaque composition.
One study reported a non-significant decrease in PV in
a subgroup with <100 mg/dL LDL-C levels at follow-up
and in a subgroup with >6 months of statin therapy;
these data were probably due to a relatively small sample
size and non-consideration of the consequences of statin
dose [6]. Based on the achieved LDL-C levels, our sub-
group analyses demonstrated significant plaque regres-
sion at a follow-up LDL-C level of <100 mg/dL. Those
results support the efficacy of Adult Treatment Panel III
(ATP III) Cholesterol Guidelines and improve the prac-
tice of lipid lowering with statins [50]. Recently, one
IVUS study have reported that a positive association was
noted between the changes in LDL-C and plaque volume
[30]. Some landmark studies have also shown that higheved in patients taking one statin
I2 index PV change (95% CI) P
0% −5.3 mm3 (−7.2, –3.3) <0.001
0% −8.8 mm3 (−13.7, –3.9) 0.0004
0% −4.1 mm3 (−6.8, –1.5) 0.003
a pectoris; I2 index: degree of heterogeneity in the meta-analysis.
Figure 4 Effects of statins on plaque composition.
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better for reducing cardiovascular adverse events in
patients with cardiovascular disease [51-53]. Previous
analyses suggest that benefit can be achieved by treating
older patients with CHD more aggressively to reduce
LDL-C levels to <100 mg/dL [54]. Those benefits may be
explained by the results in the present study which con-
firm that statin therapy at high dose over the long term
are better for retarding and reversing atherosclerosis.
The present study showed that, by appropriatelyTable 2 Stratified analyses by dose and duration of follow-up





Abbreviations: PV, plaque volume. Subgroup 1: ≤10 mg/day of atorvastatin or an eq
≤10 mg/day of atorvastatin or an equivalent dose of other statins and >6 months o
other statins and ≤6 months of follow-up; subgroup 4: >10 mg/day of atorvastatin
degree of heterogeneity in the meta-analysis.selecting the regimen, statins can be used to reduce the
atheroma burden for secondary prevention. The present
study was based on large numbers of patients and had
significant statistical power. No heterogeneity in treat-
ment effects was observed for the main endpoints. More-
over, the funnel plot did not show asymmetry consistent
with publication bias, and the fail-safe N for the main
endpoints was relatively large. Additionally, our results
were not influenced by including the results of the EN-
CORE II study using 0.2–0.8 mg/day of cerivastatin [9].of statin therapy
I2 index PV change (95% CI) P
0% −5.4 mm3 (−13.8, 3.0) 0.21
59% −7.8 mm3 (−20.2, 4.5) 0.21
0% −5.6 mm3 (−22.3, 11.2) 0.52
0% −5.2 mm3 (−7.3, –3.1) <0.001
uivalent dose of other statins and ≤6 months of follow-up; subgroup 2:
f follow-up; subgroup 3: >10 mg/day of atorvastatin or an equivalent dose of
or an equivalent dose of other statins and >6 months of follow-up. I2 index:
Table 3 Stratified analyses by LDL-C levels at follow-up
Subgroup Number of studies Number of patients I2 index PV change (95% CI) P
≤70 mg/dL of LDL-C 4 429 0% −5.9 mm3 (−9.6, –2.3) <0.001
70–100 mg/dL of LDL-C 13 1,372 9% −5.7 mm3 (−8.6, –2.7) <0.001
≥100 mg/dL of LDL-C 5 370 0% −4.2 mm3 (−9.9, 1.5) 0.15
Abbreviations: LDL-C, low-density lipoprotein-cholesterol; PV, plaque volume. I2 index: degree of heterogeneity in the meta-analysis.
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decrease plaque size, lipid content, and the thickness of
the fibrous cap [55-57]. Nevertheless, the mechanisms
by which statins contribute to plaque stabilization and
atherosclerotic regression are incompletely understood.
Recently, OCT, integrated backscatter intravascular
ultrasound (IB-IVUS), VH-IVUS, and angioscopy have
been shown to provide in-vivo real-time qualitative in-
formation of atheromas, such as lipid content, fibrous-
cap thickness, calcification, macrophage infiltration,
thrombosis, and rupture [58-60]. Therefore, investigators
could design large-scale studies to elucidate the changes
in the size and composition of plaques after LLT with
statins by combining these catheter-based intravascular
imaging tools.
Some researchers have paid close attention to the
pleiotropic effects of statins that are independent of lipid
lowering effects. These include immune modulation, in-
hibition of the proliferation and migration of smooth
muscle cells, and inhibition of angiogenesis [61-65]. The
primary action of statins is a cholesterol-dependent ef-
fect: inhibition of the synthesis of L-mevalonate (a pre-
cursor of cholesterol). The secondary actions are
pleiotropic: inhibition of the synthesis of isoprenoids
such as farnesyl pyrophosphate and geranylgeranyl pyro-
phosphate (which are essential for membrane transloca-
tion and the biological activity of members of the
GTPase family) [66,67]. Williams et al. documented that
pravastatin-treated monkeys had atherosclerotic lesions
with less neovascularization and less infiltration of
macrophages independent of plasma concentrations of
lipoproteins [37]. Atorvastatin treatment has been shown
to dose-dependently reduce the level of a serum marker
of oxidative stress [68]. Furthermore, those pleiotropic
effects of statins are often larger with high doses of sta-
tins, and there may be individual differences among dif-
ferent statins [69]. The present study has shown that
regimens employing high doses of statin result in plaque
regression in subjects with CHD. The dose-dependent
pleiotropic effects of statins may be one of the explana-
tions for our findings [70]. In the present study, greater
benefit was noted among patients with ACS, which led to
an improvement in outcome [71]. The pleiotropic effects
of statins (particularly their anti-inflammatory and
antithrombotic properties) have been invoked to explain
the greater benefits seen in ACS [72,73]. However, itremains unclear which statin has the greatest and most
rapid pleiotropic effects. Large, prospective, controlled
studies are needed to determine the role of the pleio-
tropic effects of statins on atherosclerosis.
Our systematic review and meta-analysis had limita-
tions. First, as is true with all systematic reviewed and
meta-analyses, our study may have been affected by pub-
lication bias (though we did not find evidence of such
bias). Second, the inclusion criteria of patients in pri-
mary studies (including those in the present study) were
not standardized (e.g., LDL-C levels at baseline and clin-
ical presentation). Third, although the studies included
in this meta-analysis were homogeneous, variations in
the dose, type, and duration of statin use among studies
might have affected our results. Our random-effects
model attempted to account for between-study variabil-
ity, and the effects of this heterogeneity were examined.Conclusions
Statins are prescribed extensively for the treatment of
hypercholesterolemia. Our meta-analysis demonstrated
that statin therapy (especially at a high dose and of long
duration) can induce a significant decrease in PV. Based
on the achieved LDL-C levels, subgroup analyses
demonstrated significant plaque regression at a follow-
up LDL-C level of <100 mg/dL. We also showed that
statin treatment can induce a twofold decrease in PV in
patients with ACS compared with that seen in patients
with SAP. However, no significant change in plaque
composition was seen after statin therapy.Additional files
Additional file 1: Table S1. General characteristic of the 5 studies
including 7 groups without formal analysis.
Additional file 2: Table S2. (VH)-IVUS findings at baseline and follow-
up in patients taking one statin from 5 studies without formal analysis.
Additional file 3: Table S3. General characteristic of the included
studies.Abbreviations
ACS: Acute coronary syndrome; CHD: Coronary heart disease; CI: Confidence
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density lipoprotein-cholesterol; LLT: Lipid-lowering therapy; OCT: Optical
coherence tomography; PV: Plaque volume; SAP: Stable angina pectoris;
VH: Virtual histology.
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